MONEY

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Read More

Tags:

Previous Article

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts...

Next Article

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-M...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Sopra Steria: Weekly Disclosure of Transactions in Own Shares From September 23rd to September 27th, 2024

Sopra Steria: Weekly Disclosure of Transactions in Own ...

Tomas Kauer - Mode... Oct 1, 2024

Greenfire Announces Date for Rights Plan Hearing with the Alberta Securities Commission and Resignation of Two Directors

Greenfire Announces Date for Rights Plan Hearing with t...

Tomas Kauer - Mode... Oct 1, 2024

REE Automotive Announces Global Manufacturing Agreement with Leading Automotive Supplier Motherson Group Making Strategic Investment in a $45.35 Million Registered Direct Offering Led By M&G

REE Automotive Announces Global Manufacturing Agreement...

Tomas Kauer - Mode... Sep 17, 2024